Pharmacology of emerging novel platelet inhibitors
- 31 August 2008
- journal article
- review article
- Published by Elsevier BV in American Heart Journal
- Vol. 156 (2), 10S-15S
- https://doi.org/10.1016/j.ahj.2008.06.004
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose ClopidogrelJournal of Cardiovascular Pharmacology, 2007
- Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3ABlood, 2007
- The Disposition of Prasugrel, a Novel Thienopyridine, in HumansDrug Metabolism and Disposition, 2007
- AZD6140Expert Opinion on Investigational Drugs, 2007
- INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450Drug Metabolism and Disposition, 2006
- Preclinical and Clinical Studies with Selective Reversible Direct P2Y12AntagonistsSeminars in Thrombosis and Hemostasis, 2005
- Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y12Receptor Antagonist ActivitySeminars in Thrombosis and Hemostasis, 2005
- Therapeutic potential of protease-activated receptor-1 antagonistsExpert Opinion on Investigational Drugs, 2003
- Antagonists of the Platelet P2T Receptor: A Novel Approach to Antithrombotic TherapyJournal of Medicinal Chemistry, 1999
- Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activationCell, 1991